# US 2021/0079042 A1 · Peptide hydrogels and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079042 A1
- Document ID: US20210079042A1
- Status: Published application
- Kind: A1
- Application number: 16/954,492
- Filed: 2017-12-17
- Published: 2021-03-18
- Earliest claimed: 2017-12-17
- Assignees: The United State of America, as represented by the Secretary, Department of; Health and Human Services
- Applicants: The United State of America, as represented by the Secretary, Department of Health and Human Service
- Inventors: Joel Schneider; Scott Walsh; Stephen Miller; Yuji Yamada; Scott Durum; Caroline Andrews; Wenqing Li; Julie Hixon; Steven Tau
- Web page: https://patentgrep.com/patent/US20210079042A1

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/001: {by chemical synthesis}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/42: Cancer antigens
- A61L 27/22: Polypeptides or derivatives thereof {, e.g. degradation products}
- A61L 27/227: {Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24}
- A61L 27/52: Hydrogels or hydrocolloids
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- C07K 14/5418: {IL-7}
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C12N 5/0018: {Culture media for cell or tissue culture (media for specific animal cell type C12N5/06)}
- C12N 5/0062: {General methods for three-dimensional culture}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61L 2400/06: Flowable or injectable implant compositions
- C07K 2319/00: Fusion polypeptide
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/35: containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
- C08L 2203/02: for biomedical use
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2513/00: 3D culture
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

This disclosure provides novel anionic amphiphilic β-hairpin peptides that self-assemble under appropriate conditions to form a reversible gel-sol hydrogel that can be used, for example, to readily deliver protein therapeutics and cells by injection to a target location in a subject.

## Claims

### Claim 1

An isolated peptide, comprising or consisting of an amino acid sequence set forth as:
(1)
XBXZXZXBX-[DPP, DPG, or NG]-XBXZXBXBX
wherein
each X is independently selected from any one of L, I, T, and V;
each B is independently selected from any one of D, E, and S;
each Z is independently selected from any one of D, E, Q, N, T, K, R, and S;
the DP is a proline that is a D amino acid;
the C-terminus of the peptide is amidated or free carboxylic acid;
the N-terminus of the peptide is acetylated or free amine; and
the peptide is no more than 50 amino acids in length.

### Claim 2 (depends on 1)

The isolated peptide of claim 1, comprising or consisting of an amino acid sequence set forth as one of:
(1a)
XBXZXZXBXDPPXBXZXBXBX;
(2a)
XBXZXZXBXDPGXBXZXBXBX;
or
(3a)
(SEQ ID NO: 1)
XBXZXZXBX NGXBXZXBXBX.

### Claim 3 (depends on 1)

The isolated peptide of claim 1, comprising or consisting of an amino acid sequence set forth as one of:
(1b)
XBXSXSXBXDPPXBXSXBXBX;
(2b)
XBXSXSXBXDPGXBXSXBXBX;
or
(3b)
(SEQ ID NO: 2)
XBXSXSXBX NGXBXSXBXBX.

### Claim 4 (depends on 1)

The isolated peptide of claim 1, comprising or consisting of an amino acid sequence set forth as one of:
(1c)
XEXSXSXEXDPPXEXSXEXEX;
(2c)
XEXSXSXEXDPGXEXSXEXEX;
or
(3c)
(SEQ ID NO: 3)
XEXSXSXEX NGXEXSXEXEX.

### Claim 5 (depends on 1)

The isolated peptide of claim 1, comprising an amino acid sequence set forth as one of:
(1d)
VEVSVSVEVDPPTEVSVEVEV;
(2d)
VEVSVSVEVDPGTEVSVEVEV;
or
(3d)
(SEQ ID NO: 4)
VEVSVSVEV NGTEVSVEVEV.

### Claim 6 (depends on 5)

The isolated peptide of claim 5, consisting of the AcVES3 peptide:
Ac-VEVSVSVEVDPPTEVSVEVEV-NH2.

### Claim 7 (depends on 1)

The isolated peptide of claim 1, wherein the C-terminus of the peptide is amidated and the N-terminus of the peptide is acetylated.

### Claim 8 (depends on 1)

The isolated peptide of claim 1, wherein the peptide forms an amphiphilic β-hairpin conformation in an aqueous solution comprising 150 mM NaCl and a pH of 7.4 at 25-37° C.

### Claim 9 (depends on 1)

The isolated peptide of claim 1, wherein:
an aqueous solution containing 2% w/v of the peptide and 150 mM NaCl and a pH of 7.4 forms a peptide hydrogel comprising a fibrillar network of a plurality of the peptide when incubated at 25-37° C. in a container; and
the hydrogel undergoes a gel-sol phase transition upon application of shear stress, and a sol-gel phase transition upon removal of the shear stress.

### Claim 10 (depends on 1)

The isolated peptide of claim 1, wherein the peptide is from 20 to 50 amino acids in length.

### Claim 11 (depends on 1)

A peptide hydrogel formed with the isolated peptide of claim 1.

### Claim 12 (depends on 11)

The peptide hydrogel of claim 11, further comprising at least one heterologous protein dispersed within the peptide hydrogel.

### Claim 13 (depends on 12)

The peptide hydrogel of claim 12, wherein the heterologous protein is a therapeutic protein.

### Claim 14 (depends on 13)

The peptide hydrogel of claim 13, wherein the therapeutic protein is a cytokine.

### Claim 15 (depends on 12)

The peptide hydrogel of claim 12, wherein the heterologous protein is one of IL-7, IL-2, IL-15, or a heterodimer of IL-15 and IL-15Rα.

### Claim 16

(canceled)

### Claim 17 (depends on 12)

The peptide hydrogel of claim 12, wherein the heterologous protein is fused to a peptide tag having a net positive charge that increases retention of the heterologous protein in the hydrogel.

### Claim 18

(canceled)

### Claim 19 (depends on 12)

The peptide hydrogel of claim 12, wherein the heterologous protein is fused to a peptide tag having a net negative charge that decreases retention of the heterologous protein in the hydrogel.

### Claim 20

(canceled)

### Claim 21 (depends on 12)

A syringe, containing the peptide hydrogel of claim 12.

### Claim 22 (depends on 12)

A method of administrating a heterologous protein to a subject, comprising administering the peptide hydrogel of claim 12 to the subject.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

The isolated peptide of claim 1, fused to an integrin binding peptide.

### Claim 25 (depends on 24)

The isolated peptide of claim 24, wherein the isolated peptide is fused to the integrin binding peptide by a heterologous peptide linker.

### Claim 26 (depends on 24)

The isolated peptide of claim 24, wherein the amino acid sequence of the integrin binding peptide is set forth as any one of RGDV (SEQ ID NO: 5), KQAGDV (SEQ ID NO: 6), RLD, KRLDGS (SEQ ID NO: 7), LDV, IDS, LET, IET, YYDLR (SEQ ID NO: 8), or FYFDLR (SEQ ID NO: 9).

### Claim 27 (depends on 26)

The isolated peptide of claim 26, wherein the amino acid sequence of the integrin binding peptide is set forth as RGDV (SEQ ID NO: 5).

### Claim 28 (depends on 24)

The isolated peptide of claim 24, wherein the isolated peptide fused to the integrin binding peptide comprises the amino acid sequence set forth as:
YEVSVSYEVDPPTEVSYEYEVGGGGRGDV.

### Claim 29 (depends on 28)

The isolated peptide of claim 28, wherein the isolated peptide fused to the integrin binding peptide consists of the AcVES3-RGDV peptide:
Ac-VEVSVSVEVDPPTEVSYEYEVGGGGRGDV-NH2.

### Claim 30 (depends on 24)

A peptide hydrogel formed with the isolated peptide of claim 24.

### Claim 31 (depends on 30)

The peptide hydrogel of claim 30, further comprising:
mammalian cells dispersed within the peptide hydrogel, wherein the mammalian cells comprise a cell surface comprising one or more integrin proteins that bind to the integrin binding peptide.

### Claim 32 (depends on 31)

The peptide hydrogel of claim 31, wherein the mammalian cells express a therapeutic protein.

### Claim 33 (depends on 31)

The peptide hydrogel of claim 31, wherein the mammalian cells are chimeric antigen receptor (CAR) T cells.

### Claim 34 (depends on 31)

The peptide hydrogel of claim 31, wherein binding of the integrin binding peptide to the one or more integrin proteins increases retention of the heterologous cell in the peptide hydrogel.

### Claim 35 (depends on 31)

A syringe, containing the peptide hydrogel of claim 31.

### Claim 36 (depends on 31)

A method of administrating a heterologous cell to a subject, comprising administering the peptide hydrogel of claim 31 to the subject.

### Claim at position 37

-38. (canceled)

### Claim 39 (depends on 24)

A method of culturing mammalian cells in a three-dimensional matrix, comprising:
mixing the peptide of claim 24 and mammalian cells under conditions sufficient to form a peptide hydrogel encapsulating the mammalian cells, wherein the mammalian cells comprise a cell surface comprising one or more integrin proteins that bind to the integrin binding peptide fused to the AcVES3 peptide; and
incubating the mammalian cells under conditions sufficient for cell growth and proliferation.

### Claim 40 (depends on 11)

The peptide hydrogel of claim 11, wherein the hydrogel undergoes a gel-sol phase transition upon application of shear stress, and a sol-gel phase transition upon removal of the shear stress;
the hydrogel comprises a storage modulus of greater than 40 Pascal in the absence of shear;
the hydrogel comprises from about 10 mM to about 400 mM NaCl and a pH of from about 7.0 to about 9.0;
the hydrogel comprises from about 0.25% to about 4.0% w/v peptide; and/or
the hydrogel does not induce a lymphocytic immune response when administered to a subject.

### Claim at position 40

-46. (canceled)
